The hypothesis that CTLA-4 antibody-containing regimens may be effective for patients with TTF-1-negative non-squamous NSCLC is suggested, although the present study failed to identify the immune checkpoint inhibitor therapy associated with improved survival.
Minehiko Inomata, Yutaro Moriyasu, T. Tsuda et al.· Cancer Treatment and Researc...· 0 citations
Progressive pulmonary fibrosis (PPF) is a fatal lung condition characterized by persistent inflammation and progressive fibrotic remodeling. Monocyte-derived alveolar macrophages (Mo-AMs) are key drivers of fibrogenesis; however, the mechanisms underlying their persistence in fibrotic lungs remain unclear. Using lineag...
K. Kase, Satoshi Watanabe, Masafumi Horie et al.· American Journal of Physiolo...· 0 citations
Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1%, a population with high unmet need. Here we report long-term clinical outcomes with first-...
Makoto Nishio, H. Hayashi, Yasushi Goto et al.· International Journal of Cli...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.